Literature DB >> 15710465

Converting relapsing remitting to secondary progressive experimental allergic encephalomyelitis (EAE) by ultraviolet B irradiation.

Ikuo Tsunoda1, Li-Qing Kuang, Isaac Z M Igenge, Robert S Fujinami.   

Abstract

We induced experimental allergic encephalomyelitis (EAE) in SJL/J mice, an animal model for multiple sclerosis (MS), using myelin oligodendrocyte glycoprotein (MOG)(92-106) peptide, following ultraviolet (UV) irradiation. While all control mice developed relapsing-remitting (RR)-EAE, UV irradiation induced secondary progressive (SP)-EAE in some of the mice. Although mild demyelination was observed with T cell infiltration in RR-EAE, large demyelinating lesions developed in SP-EAE with massive macrophage and neutrophil infiltration and immunoglobulin deposition, but with little T cell infiltration. UV irradiation induced higher anti-MOG antibody responses. In SP-EAE, lymphoproliferative responses and interferon-gamma production were decreased without alteration of interleukin-4.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15710465     DOI: 10.1016/j.jneuroim.2004.11.007

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

1.  Contrasting roles for axonal degeneration in an autoimmune versus viral model of multiple sclerosis: When can axonal injury be beneficial?

Authors:  Ikuo Tsunoda; Tomoko Tanaka; Emily Jane Terry; Robert S Fujinami
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

2.  Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design.

Authors:  Mitchell R Emerson; Ryan J Gallagher; Janet G Marquis; Steven M LeVine
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

3.  Immunopathological patterns from EAE and Theiler's virus infection: Is multiple sclerosis a homogenous 1-stage or heterogenous 2-stage disease?

Authors:  Nicholas E Martinez; Fumitaka Sato; Seiichi Omura; Alireza Minagar; J Steven Alexander; Ikuo Tsunoda
Journal:  Pathophysiology       Date:  2012-05-26

4.  Massive apoptosis in lymphoid organs in animal models for primary and secondary progressive multiple sclerosis.

Authors:  Ikuo Tsunoda; Jane E Libbey; Li-Qing Kuang; Emily Jane Terry; Robert S Fujinami
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

5.  Role of CD5+ B-1 cells in EAE pathogenesis.

Authors:  Lisa K Peterson; Ikuo Tsunoda; Robert S Fujinami
Journal:  Autoimmunity       Date:  2008-08       Impact factor: 2.815

6.  In trans T cell tolerance exacerbates experimental allergic encephalomyelitis by interfering with protective antibody responses.

Authors:  Jason A Cascio; Marie-Therese Khairallah; Xiaoxiao Wan; Weirong Chen; Linda M Rowland; Mermagya Dhakal; Mindy M Miller; Habib Zaghouani
Journal:  J Neuroimmunol       Date:  2013-10-05       Impact factor: 3.478

7.  Role of B:T cell ratio in suppression of clinical signs: a model for silent MS.

Authors:  Lisa K Peterson; Ikuo Tsunoda; Jane E Libbey; Robert S Fujinami
Journal:  Exp Mol Pathol       Date:  2008-04-08       Impact factor: 3.362

8.  Sequential polymicrobial infections lead to CNS inflammatory disease: possible involvement of bystander activation in heterologous immunity.

Authors:  Ikuo Tsunoda; Jane E Libbey; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2007-07-02       Impact factor: 3.478

9.  Targeting inflammatory demyelinating lesions to sites of Wallerian degeneration.

Authors:  Ikuo Tsunoda; Tomoko Tanaka; Yukio Saijoh; Robert S Fujinami
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

10.  Regulation of an autoimmune model for multiple sclerosis in Th2-biased GATA3 transgenic mice.

Authors:  Viromi Fernando; Seiichi Omura; Fumitaka Sato; Eiichiro Kawai; Nicholas E Martinez; Sadie Faith Elliott; Keigyou Yoh; Satoru Takahashi; Ikuo Tsunoda
Journal:  Int J Mol Sci       Date:  2014-01-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.